Avoro Capital Advisors LLC Buys 24,444 Shares of Xenon Pharmaceuticals Inc. $XENE

Avoro Capital Advisors LLC increased its stake in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) by 0.5% in the 4th quarter, HoldingsChannel.com reports. The firm owned 5,424,444 shares of the biopharmaceutical company’s stock after acquiring an additional 24,444 shares during the period. Xenon Pharmaceuticals comprises 2.3% of Avoro Capital Advisors LLC’s investment portfolio, making the stock its 15th biggest position. Avoro Capital Advisors LLC owned approximately 0.07% of Xenon Pharmaceuticals worth $243,124,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. JPMorgan Chase & Co. raised its position in shares of Xenon Pharmaceuticals by 11.3% during the 3rd quarter. JPMorgan Chase & Co. now owns 1,399,033 shares of the biopharmaceutical company’s stock valued at $56,171,000 after acquiring an additional 142,452 shares during the last quarter. Neo Ivy Capital Management bought a new stake in shares of Xenon Pharmaceuticals during the 3rd quarter valued at $2,001,000. HighVista Strategies LLC raised its position in shares of Xenon Pharmaceuticals by 80.2% during the 3rd quarter. HighVista Strategies LLC now owns 82,190 shares of the biopharmaceutical company’s stock valued at $3,300,000 after acquiring an additional 36,570 shares during the last quarter. Assenagon Asset Management S.A. bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $5,342,000. Finally, Peregrine Capital Management LLC bought a new stake in shares of Xenon Pharmaceuticals during the 4th quarter valued at $7,837,000. Institutional investors own 95.45% of the company’s stock.

Wall Street Analyst Weigh In

XENE has been the subject of several recent research reports. Guggenheim reiterated a “buy” rating and set a $90.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Wolfe Research initiated coverage on shares of Xenon Pharmaceuticals in a research report on Monday, February 23rd. They set an “outperform” rating and a $60.00 target price for the company. HC Wainwright upped their target price on shares of Xenon Pharmaceuticals from $53.00 to $74.00 and gave the company a “buy” rating in a research report on Tuesday, March 10th. Jefferies Financial Group set a $100.00 target price on shares of Xenon Pharmaceuticals in a research report on Monday, March 9th. Finally, Robert W. Baird upped their target price on shares of Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a research report on Monday, March 9th. Two research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Buy” and a consensus price target of $77.20.

Xenon Pharmaceuticals Stock Down 0.8%

XENE opened at $51.99 on Wednesday. Xenon Pharmaceuticals Inc. has a 12 month low of $30.00 and a 12 month high of $63.95. The company has a fifty day simple moving average of $55.23 and a 200 day simple moving average of $49.11. The stock has a market cap of $5.03 billion, a P/E ratio of -11.06 and a beta of 0.62.

Xenon Pharmaceuticals (NASDAQ:XENE) last released its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($1.17) EPS for the quarter, meeting analysts’ consensus estimates of ($1.17). During the same quarter in the prior year, the firm posted ($0.83) earnings per share. On average, equities research analysts expect that Xenon Pharmaceuticals Inc. will post -4.92 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Gary Patou sold 1,322 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total value of $70,251.08. Following the completion of the sale, the director owned 24,896 shares in the company, valued at $1,322,973.44. This represents a 5.04% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gillian Cannon sold 1,190 shares of the company’s stock in a transaction on Friday, June 5th. The shares were sold at an average price of $53.14, for a total transaction of $63,236.60. Following the completion of the sale, the director owned 1,455 shares of the company’s stock, valued at approximately $77,318.70. This represents a 44.99% decrease in their position. The disclosure for this sale is available in the SEC filing. 4.07% of the stock is owned by corporate insiders.

Xenon Pharmaceuticals Profile

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.